EP3124080A1 — Semisynthetic bile acids for injection lipolysis
Assigned to Merz Pharma GmbH and Co KGaA · Expires 2017-02-01 · 9y expired
What this patent protects
The present invention relates to a composition comprising a compound or a pharmaceutically acceptable salt thereof having a structure according to formula (I) wherein R1 is an unsubstituted or substituted C 1-4 alkyl residue and residues R2-R5 are defined as specified in t…
USPTO Abstract
The present invention relates to a composition comprising a compound or a pharmaceutically acceptable salt thereof having a structure according to formula (I) wherein R1 is an unsubstituted or substituted C 1-4 alkyl residue and residues R2-R5 are defined as specified in the description and at least one further component C for use in a method for local treating or preventing a condition associated with an undesired local subcutaneous fat deposit in a mammal, wherein said compound is injected into said local subcutaneous fat deposit aiming for its reduction. Further, the present invention relates to the cosmetic use of such composition.
Drugs covered by this patent
- Ocaliva (OBETICHOLIC ACID) · Intercept Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.